A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Clinical trial NCT07300085 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07300085
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-08
- Primary completion
- 2026-12-31
- Enrollment
- 710
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.